

# Use of Remifentanyl for Open in utero Fetal Myelomeningocele Repair Maintains Uterine Relaxation with Reduced Volatile Anesthetic Concentration

Benjamin J. Marsh<sup>a</sup> Jina Sinskey<sup>a</sup> Elizabeth L. Whitlock<sup>a</sup> Marla B. Ferschl<sup>a</sup>  
Mark D. Rollins<sup>b</sup>

<sup>a</sup>Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA, USA;

<sup>b</sup>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA

## Keywords

Fetal anesthesia · Fetal surgery · Myelomeningocele ·  
Umbilical artery flow · Uterine relaxation

## Abstract

**Introduction:** Open fetal repair of myelomeningocele (MMC) is an option for prenatally diagnosed spina bifida. Historically, high-dose volatile anesthetic was used for uterine relaxation but is associated with fetal cardiovascular depression. We examined the impact of administering a supplemental remifentanyl infusion on the concentration of inhaled anesthetic required for intraoperative uterine relaxation. **Methods:** We retrospectively analyzed 22 consecutive patients who underwent open fetal MMC repair with desflurane anesthesia from 2014 to 2018. The anesthetic protocol was modified to include high-dose opioid with remifentanyl in 2016. We examined intraoperative end-tidal desflurane concentrations, vasopressor use, incidence of umbilical artery Doppler abnormalities, and incidence of preterm labor and delivery. **Results:** Patients ( $n = 11$ ) who received desflurane and remifentanyl (Des/Remi) were compared to patients ( $n = 11$ ) who

received desflurane (Des) alone. Intraoperatively, the maximum end-tidal desflurane required to maintain uterine relaxation was lower in the Des/Remi group ( $7.9 \pm 2.2\%$  vs.  $13.1 \pm 1.2\%$ ,  $p < 0.001$ ). The mean phenylephrine infusion rate was also lower in the Des/Remi group ( $36 \pm 14$  vs.  $53 \pm 10$  mcg/min,  $p = 0.004$ ). **Discussion:** Use of opioid with supplemental remifentanyl was associated with lower volatile anesthetic dosing and decreased vasopressor use; fetal outcomes were not different. Remifentanyl may allow for less volatile anesthetic use while maintaining adequate uterine relaxation.

© 2020 S. Karger AG, Basel

## Introduction

Myelomeningocele (MMC) is a neural tube defect affecting 5–10 pregnancies per 10,000 in the USA [1]. Compared to postnatal closure, open fetal surgery between 19 and 26 weeks of gestation for MMC repair improves postnatal outcomes [2]. Accordingly, the number of centers performing open MMC repair has increased [3, 4], and new anesthetic techniques are being examined [5].

Maintaining maternal and fetal stability during open repair while facilitating surgical exposure presents unique challenges for the anesthesiologist. Profound uterine relaxation is required for appropriate surgical conditions and adequate uterine perfusion [6]. Historically, during the Management of Myelomeningocele Study (MOMS) trial, high maternal doses of inhaled anesthetic agents (>2 minimum alveolar concentration [MAC]) were used for uterine relaxation, and intraoperative opioids were minimized in an effort to allow easier maintenance of maternal blood pressure [2]. However, use of high-dose vapor is associated with fetal cardiovascular depression [6–9] and may also cause abnormal umbilical artery flow [10]. In the USA, anesthesia for open fetal surgery was no longer standardized following the MOMS trial [2].

Adding supplemental infusions of propofol and remifentanyl to a volatile anesthetic-based technique improves intraoperative fetal stability [5]. In an animal model, this technique is associated with improved hemodynamics, uterine blood flow, and fetal acid-base status compared to high-dose volatile anesthetic alone [11]. However, it is not clear if both propofol and remifentanyl are necessary to achieve the desired reduction in volatile anesthetic concentration required for maintaining uterine relaxation. Propofol decreases human uterine muscle contractility in vitro [12, 13], but due to its high plasma protein binding (>95%), the free propofol concentration in the plasma is too low to affect uterine tone at clinically relevant dose ranges [13]. Propofol is also a myocardial depressant and may have negative effects on both mother and fetus. Opioid receptors have been identified on human myometrium and, when activated, lead to relaxation in vitro [14], suggesting a potential benefit of increasing intraoperative opioid administration.

As a site member of the MOMS trial, we initially used and continued to use a high-dose volatile anesthetic-based technique with minimal opioid administration until 2016 [2]. With increasing evidence that a high-dose volatile technique might negatively impact the fetus [5], we changed our practice from a primarily high-dose volatile anesthetic to one that was supplemented with significant intraoperative opioid administration. Following the practice change, fentanyl was administered at induction with the initiation of a remifentanyl maintenance infusion to potentially decrease inhaled anesthetic requirement.

In this before-after study, our primary aim was to determine the impact of supplemental opioid on the des-

flurane concentration required for adequate intraoperative uterine relaxation. Additionally, we compared the effects of this technique on maternal hemodynamics and fetal parameters during open fetal surgery.

## Methods

### *Study Population*

After IRB approval, we performed a retrospective review of all 24 patients who underwent open fetal MMC repair between 2014 and 2018 at a single US tertiary care medical center, with the open fetal surgery anesthetic protocol change occurring in early 2016. All surgeries included in the study were performed by 1 primary surgeon, whose surgical approach remained consistent over the study period and who had been in practice as a fetal surgeon since the start of the MOMS trial. Two patients who received sevoflurane instead of desflurane were excluded from the analysis, leaving 22 patients for consideration. We followed the STROBE guidelines in completing this study [15].

### *Maternal-Fetal Anesthetic Management*

All patients scheduled for open fetal MMC repair underwent routine preoperative assessment by a multidisciplinary team. A thorough in-person preoperative history and physical examination were performed by an anesthesiologist within 2 weeks prior to the surgery date and again on the day of surgery. Before induction of maternal general anesthesia, a lumbar epidural was placed for postoperative pain management. All patients underwent general endotracheal anesthesia with a rapid sequence induction. For anesthesia maintenance, all patients received high-dose desflurane without a remifentanyl infusion prior to 2016, as previously detailed [2,6]. Although intravenous fentanyl administration was not standardized, total doses remained  $\leq 100$  mcg for all of these patients, with the majority of patients not receiving any fentanyl until after uterine closure. In 2016, the anesthetic protocol was altered, with the administration of 250 mcg of intravenous fentanyl on induction, immediately followed by initiation of an intravenous infusion of remifentanyl at 0.3 mcg/kg/min, which remained constant throughout the case until emergence. Inhaled desflurane was administered to achieve adequate uterine relaxation. Prior to 2016, our institutional protocol was to increase desflurane to near 2 MAC just prior to uterine exposure and titrate the vapor concentration up or down based on the surgeon's evaluation of the uterus. After the protocol change in 2016, where patients were administered a remifentanyl infusion, the desflurane was typically increased to 1–1.5 MAC just prior to uterine exposure, and the concentration titrated up or down based on surgical feedback of uterine tone. All patients received a phenylephrine infusion to maintain their mean arterial pressure (MAP) within 10% of baseline as well as glycopyrrolate or ephedrine boluses to maintain maternal heart rate (HR) near baseline (typically within 20%). This hemodynamic protocol is similar to the recent guidelines for the management of maternal hemodynamics during cesarean delivery [16]. Intermittent fetal echocardiography and umbilical artery Doppler ultrasound were used for fetal monitoring. For fetal anesthesia, intramuscular fentanyl and rocuronium were administered to the fetus in all cases following maternal hysterotomy. Additional uterine tocolysis included preoperative indomethacin and administra-

**Table 1.** Preoperative data of patients receiving desflurane alone (Des) versus desflurane and remifentanyl (Des/Remi)

	Des	Des/Remi	<i>p</i> value
Total number of patients	11	11	
Demographics			
Year of surgery			
2014–2015	11	0	
2016–2018	0	11	
Maternal age, years	31.0±5.4	30.7±4.5	0.90
Maternal weight, kg	78.8±11.6	74.2±9.6	0.32
Gestational age at surgery, weeks	24.0±1.3	24.3±1.2	0.55
Preoperative maternal heart rate, beats/min	84±16	79±13	0.42

Continuous data are displayed as mean ± SD. Categorical variables were compared with Fisher's exact test due to small sample size.

tion of intravenous magnesium sulfate (6 g load over 20 min, followed by an infusion of 2 g per hour) at start of uterine closure. Following the completion of uterine closure and magnesium load, the desflurane concentration was gradually reduced during abdominal closure in preparation for emergence. During this time, the epidural analgesia was initiated.

Medical records were reviewed to determine intraoperative end-tidal desflurane concentrations, vasopressor use, incidence of umbilical artery flow abnormalities, presence of intraoperative uterine contractions, and incidence of preterm labor and delivery. MAC was determined by dividing end-tidal % desflurane by 6.6% [17].

#### Statistical Analysis

Data are reported as mean ± SD or median (interquartile range) for continuous variables, depending on normality, and as count (percentage) for categorical variables. This study was designed as a retrospective superiority trial with the prespecified primary outcome as maximum end-tidal percentage of desflurane between procedure start (i.e., surgical incision) and procedure end (i.e., surgical closure), compared between patients who received a remifentanyl infusion versus those who did not. Maximum end-tidal concentration of desflurane was chosen as an endpoint to demonstrate the degree of volatile anesthetic required to maintain adequate uterine relaxation, similar to a prior study evaluating the effect of supplemental propofol and remifentanyl [5]. After confirming that the maximum end-tidal desflurane dose was normally distributed, the primary analysis used Student's *t* test for comparison.

Secondary outcome univariate analyses were performed with *t* tests or Mann-Whitney *U* tests for continuous variables, depending on normality, and Fisher's exact test for all categorical variables, given the small sample size. Data are displayed as mean ± SD, median (interquartile range), or number (percent).

Since operative duration was statistically shorter after the anesthetic practice change, we performed a post hoc sensitivity analysis adjusting the reported measurements of total volatile anesthetic concentration by operative time using linear regression. Recognizing the limitations of the small sample size, no other adjustment factors were used. All analyses were performed using Stata MP version 14 (StataCorp LP).

#### Sample Size Calculation

The sample size calculation was based on a primary outcome of maximum end-tidal desflurane percentage. Analysis of fetal anesthesia data prior to 2016 demonstrated an average maximum desflurane concentration of 13% with an SD ( $\sigma$ ) of about 1.3%. Although reflective of our recent practice, an SD of 1.3% was unexpectedly small, and we felt it was a potentially unrealistic assumption that the data incorporating the supplemental opioid would remain with an SD near this value. Consequently, we chose to use data from the 2010 article by Boat et al. [5]. In this work, the volatile-based fetal anesthesia group received a mean maximum desflurane dose of 15.8 ± 3.0% and the group that received intravenous propofol and remifentanyl had a mean maximum desflurane concentration of 10.6 ± 4.3%. This represents a 40% dose reduction in maximum desflurane concentration, which is the difference we chose to use for our sample size calculation. Using the mean value from our prior data (Group 1) combined with the unequal  $\sigma$ 's from Boat et al. [5], a 2 group Satterthwaite *t* test with a 0.05 two-sided significance level will have 88.45% power to detect a difference in means of 5.2% (the difference between a Group 1 mean,  $\mu_1$ , of 13% and a Group 2 mean,  $\mu_2$ , of 7.8%, which represents a 40% reduction), assuming that the Group 1 SD,  $\sigma_1$ , is 4.3% and the Group 2 SD,  $\sigma_2$ , is 3.0% (ratio of Group 2 to Group 1 SD is 0.698) when the sample sizes in the 2 groups are 11 and 11, respectively.

#### Results

Eleven consecutive patients who received desflurane and supplemental opioid (Des/Remi) were compared to the 11 previous patients (control) who received desflurane (Des) without remifentanyl or significant fentanyl administration prior to uterine closure. Maternal age, weight, and gestational age did not significantly differ between the groups (Table 1). Two patients had depression and 1 had asthma in the Des/Remi group. One patient had depression, 1 had asthma, and 1 had hypothyroidism in the Des group. Preoperative baseline maternal HR and

**Table 2.** Intraoperative data of patients receiving Des versus Des/Remi

Intraoperative variables	Des	Des/Remi	<i>p</i> value
Duration of anesthesia, h	3.28±0.22	3.00±0.37	0.049
Duration of surgery, h	2.69±0.26	2.30±0.31	0.005
Maximum maternal heart rate, beats/min	122 (116–138)	122 (112–129)	0.49
Minimum maternal heart rate, beats/min	62 (58–72)	52 (50–54)	0.005
Maximum maternal MAP	109 (103–118)	103 (100–119)	0.17
Minimum maternal MAP	67 (63–69)	63 (58–65)	0.075
Case-average end-tidal desflurane, %	11.0±1.2	6.7±2.1	<0.001
Maximum end-tidal desflurane, %	13.1±1.2	7.9±2.2	<0.001
Total MAC-hour desflurane exposure <sup>b</sup>	4.5±0.7	2.4±1.0	<0.001
Case-average phenylephrine rate, mcg/min	53±10	36±14	0.004
Total fentanyl dose prior to uterine closure (mcg)	0 (0–0)	250 (250–250)	<0.001
Case-average remifentanyl dose, mcg/kg/min	0 (0–0)	0.3 (0.2–0.4)	<0.001
Total glycopyrrolate dose, mg	0.4 (0–0.6)	0.6 (0.4–0.8)	0.025
Estimated blood loss, mL	300 (100–300)	100 (50–150)	0.022
Colloid volume, L	0.5 (0.5–1.0)	0.5 (0–1.0)	0.60
Crystalloid volume, L	1.3±0.5	1.0±0.6	0.26
Reversal of umbilical artery end diastolic flow	3 (27%)	2 (18%)	>0.99 <sup>a</sup>
Incidence of fetal bradycardia	0	0	>0.99

Data are displayed as mean ± SD, median (interquartile range), or number (%). Des, desflurane; Des/Remi, desflurane and remifentanyl; MAC, minimum alveolar concentration (i.e., end-tidal desflurane percentage divided by 6.6%); MAP, mean arterial pressure. <sup>a</sup> Categorical variables were compared with Fisher's exact test due to small sample size. <sup>b</sup> Exposure time from procedure start to procedure end.

MAP did not significantly differ between groups. The upper border of the fetal MMC lesion in both groups ranged from L1 to S1. Preoperative fetal echocardiography was normal in both groups except for 1 patient in the Des/Remi group notable for a small ventricular septal defect. The average gestational age at surgery was similar, 24.0 ± 1.3 weeks in the Des group versus 24.3 ± 1.2 weeks in the Des/Remi group (Table 1).

Intraoperative findings are displayed in Table 2. The maximum end-tidal desflurane required from procedure start to procedure end was lower in the Des/Remi group (7.9 ± 2.2% vs. 13.1 ± 1.2%, *p* < 0.001). The duration of surgery was 17% longer in the Des group than in the Des/Remi group (2.7 ± 0.3 vs. 2.3 ± 0.3 h, *p* = 0.005).

In addition, the Des/Remi group was administered less total desflurane than patients maintained on desflurane alone (Des group). After adjustment for procedure length, use of supplemental remifentanyl was associated with a mean 1.3 MAC-hour (95% CI: 0.5–2.0, *p* < 0.001) reduction in total desflurane use between incision and closure (Table 2). As expected, following the protocol change, total fentanyl prior to uterine closure (250 [250–250] vs. 0 [0–0] mcg, *p* < 0.001) and case-average remifentanyl (0.3 [0.2–0.4] vs. 0 [0–0] mcg/kg/min, *p* < 0.001) administration were higher in the Des/Remi group.

The average phenylephrine infusion rate was lower in the Des/Remi group (36 ± 14 vs. 53 ± 10 mcg/min, *p* = 0.004). Maximum maternal HR and maximum and minimum maternal MAP did not differ significantly between groups; minimum HR was significantly lower in the Des/Remi group, and median glycopyrrolate dose was higher. The average amount of intravenous crystalloid and colloid in each group was not different. One patient in each group received an intraoperative maternal blood transfusion.

Regarding intraoperative fetal hemodynamics, there was no difference in reversal or absence of umbilical artery end diastolic flow in either group, and there were no observed occurrences of fetal bradycardia (Table 2). Significant fetal cardiac dysfunction requiring administration of fetal resuscitation medications or altering the surgical conduct of the MMC repair was not noted in either group with intermittent intraoperative echocardiography.

Adequate uterine relaxation was achieved and maintained in both groups. No intraoperative uterine contractions were observed in either group. Estimated median intraoperative blood loss was 300 mL in the Des group versus 100 mL in the Des/Remi group (*p* = 0.02).

Additionally, there was no difference in the incidence of preterm labor or delivery between the 2 groups, and the

**Table 3.** Postoperative data of patients receiving Des versus Des/Remi

Postoperative outcomes	Des	Des/Remi	<i>p</i> value
Postop. contractions on POD #0	1 (9%)	0	>0.99 <sup>a</sup>
Contractions on POD #1–3	3 (27%)	3 (27%)	>0.99 <sup>a</sup>
Preterm labor	3 (27%)	4 (36%)	>0.99 <sup>a</sup>
Median gestational age at birth, weeks	36 (31–36)	35 (33–36)	0.54
Birth weight, g <sup>b</sup>	2,250±584	2,515±430	0.28

Data are displayed as mean±SD, median (interquartile range), or number (%). Des, desflurane; Des/Remi, desflurane and remifentanyl; POD, postoperative day. <sup>a</sup> Categorical variables were compared with Fisher's exact test due to small sample size. <sup>b</sup> Missing 3 values.

average birth weight was similar between the 2 groups (2,250 ± 584 vs. 2,515 ± 430 g, *p* = 0.28). Postoperative fetal echocardiography was unchanged in all patients (Table 3).

## Discussion

Anesthesia for open fetal surgery is an area that continues to evolve. Though historically the anesthetic practice for open fetal surgery used high-dose volatile anesthetics alone to maintain uterine relaxation, our results demonstrate that supplemental opioid utilizing a remifentanyl infusion is associated with a reduction in the concentration of anesthetic vapor dose required to maintain adequate uterine relaxation and appears to be a reliable and safe anesthetic technique. The 40% reduction in required end-tidal desflurane concentration we observed is similar to that observed in a prior study by Boat et al. [5] that administered infusions of both remifentanyl and propofol in the group requiring less volatile anesthetic.

In an effort to reduce the inhaled anesthetic agent required to maintain intraoperative uterine relaxation, we examined the addition of significant supplemental opioid using a remifentanyl infusion, without the use of supplemental propofol. The reduced volatile anesthetic concentration associated with the use of supplemental opioid allows its effects on maternal hemodynamics and fetal myocardial depression to be minimized [18]. In addition, there may be a benefit to decreasing the exposure of the developing fetal brain to potentially neurotoxic agents contained in both volatile anesthetics and propofol [19]. In 2016, the US Food and Drug Administration issued a warning that repeated or lengthy use of general anesthesia in children younger than 3 years or in pregnant women during their third trimester may affect the development of children's brains [19]. Though it is not

clear if this warning should extend into the second trimester (when most open fetal procedures are performed), minimizing exposure is likely preferable. Additionally, it is possible that the degree of neurotoxicity is dose-dependent [20, 21], so strategies to reduce total exposure by using supplemental opioid infusion of remifentanyl may be beneficial as opioids are considered non-neurotoxic.

Previous work from our institution demonstrated an increased incidence of umbilical artery flow abnormalities with the use of sevoflurane when compared to desflurane [7]. Although all volatile anesthetics are myocardial depressants, desflurane may have improved cardiac output and HR compared to sevoflurane [22]. Consequently, we elected to preferentially use desflurane for all open fetal cases unless contraindicated. Unlike other published supplemental intravenous anesthesia protocols for open fetal surgery [5], we decided to avoid propofol for our cases, as there is no evidence to support the use of propofol for uterine relaxation at typical anesthetic levels [13]. In addition, propofol is a known myocardial depressant that may contribute to unfavorable fetal hemodynamics, and propofol may be neurotoxic to the developing brain.

In our study, we also noted a statistically significant reduction in average phenylephrine rate in the patients who received remifentanyl and desflurane when compared to those who received desflurane alone (36 ± 14 vs. 53 ± 10 mcg/min, *p* = 0.004). A more stable maternal hemodynamic state that requires less vasopressor associated with the use of supplemental remifentanyl and decreased desflurane concentration may offer improved fetal perfusion and well-being during these complex procedures.

The use of supplemental remifentanyl for open fetal surgery offers several advantages in clinical practice. Remifentanyl readily crosses the placenta, providing fetal analgesia and reducing fetal sympathetic response to sur-

gery [23, 24]. It is also rapidly metabolized in both the mother and the fetus, and remifentanyl pharmacokinetics in mid-gestation during fetal surgery has been shown to be similar to the general population [25]. One drawback of remifentanyl is the potential development of opioid-induced hyperalgesia, which can lead to higher postoperative pain scores and delayed recovery after surgery [26]. Similar to patients in the MOMS trial, lumbar epidural catheters continue to be placed for all patients undergoing open fetal repair at our institution to provide opioid-sparing analgesia and reduce the potential for poorly controlled postoperative pain, increasing the risk of uterine contractions [2]. Bradycardia is another reported side effect of remifentanyl [27]. Intraoperative minimum maternal HR was 10 bpm lower in the patients who received remifentanyl, and median total intraoperative glycopyrrolate dose was 0.2 mg higher; however, we observed no significant fetal bradycardia in any of these cases. This is supported by trials examining the use of remifentanyl for labor analgesia. Although data are limited, when compared to neuraxial analgesia, there is no evidence of decreased Apgar scores, concerning cord gases, or increased need for neonatal resuscitation despite using remifentanyl through the second stage of labor [28–30].

The before/after nature of this study has some limitations. First, the procedure length was 17% longer in the Des group than in the Des/Remi group ( $2.7 \pm 0.3$  vs.  $2.3 \pm 0.3$  h,  $p = 0.005$ ). It is unclear what the cause of this result is from, as a single surgeon performed all cases in the time period and had been performing these procedures for over 10 years. However, the difference in desflurane dosing was not simply due to procedure length, as it persisted after adjustment for procedure duration. Second, the practice change included a 250 mcg bolus of fentanyl at anesthesia induction as part of the opioid supplementation of the anesthetic. However, it is unlikely that fentanyl bolus dose at anesthetic induction contributes significantly to the favorable results in the Des/Remi group, as the median duration between induction and uterine incision (53 min) implies that over 90% of fentanyl would have already been eliminated from the plasma before uterine incision [31]. Due to the retrospective design of our study, there is also the potential for time-dependent confounding and the continuation of a pre-intervention trend that could lead to bias. Another potential source of bias is the Hawthorne effect, where providers in the Des/Remi group may have unintentionally modified other aspects of their clinical management following the protocol change. Our retrospec-

tive, before and after study design limits our conclusions to be interpreted as an association with the use of remifentanyl and decreased dose of volatile anesthesia rather than a certainty of cause and effect to allow for optimal surgical conditions in these cases.

A further limitation is the small sample size. Due to the relatively rare occurrence of congenital anomalies amenable to open in utero fetal intervention, randomized controlled trials are difficult to perform at a single institution [18]. Future work we hope to pursue includes a prospective, multicenter trial validating this anesthetic technique. In addition, further studies are needed to examine the effects of remifentanyl on uterine tone and fetal cardiac function. Additionally, as more prenatal MMC repairs are being performed fetoscopically, our technique should be validated in this patient group.

In summary, we demonstrate the feasibility of an anesthetic protocol for MMC repair, which uses opioid supplementation with a remifentanyl infusion that is associated with reduced desflurane administration and yields similar intraoperative and postoperative maternal and fetal outcomes. We propose that remifentanyl offers a viable alternative to high-dose volatile anesthetic use in these procedures and also obviates the need for supplemental propofol.

### Acknowledgements

We gratefully acknowledge the Fetal Treatment Center at the University of California, San Francisco.

### Statement of Ethics

Our research complies with the guidelines for human studies, and the research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. Study protocol was approved by the Institutional Review Board, UCSF IRB #14-14813. Written informed consent was not obtained because this was a retrospective study.

### Conflict of Interest Statement

There are no conflicts of interest.

### Funding Sources

Support was provided from institutional and/or departmental sources. E.L.W. was supported by NIH KL2TR001870.

## Author Contributions

B.J.M.: This author contributed to the literature review, data collection, data analysis, primary writing, and editing of the manuscript. J.S.: This author contributed to literature review, data analysis, and editing of the manuscript. E.L.W.: This author contrib-

uted to the data analysis, statistical analysis, and editing of the manuscript. M.B.F.: This author contributed to literature review, data analysis, and editing of the manuscript, and serves as the corresponding author. M.D.R.: This author conceived the study design, and contributed to the literature review, analysis and interpretation of data, statistical analysis, and editing of the manuscript.

## References

- 1 Shaer CM, Chescheir N, Schulkin J. Myelomeningocele: a review of the epidemiology, genetics, risk factors for conception, prenatal diagnosis, and prognosis for affected individuals. *Obstet Gynecol Surv.* 2007;62(7):471–9.
- 2 Adzick NS, Thom EA, Spong CY, Brock JW 3rd, Burrows PK, Johnson MP, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. *N Engl J Med.* 2011;364(11):993–1004.
- 3 Moldenhauer JS, Adzick NS. Fetal surgery for myelomeningocele: after the management of myelomeningocele study (MOMS). *Semin Fetal Neonatal Med.* 2017;22(6):360–6.
- 4 American College of Obstetricians and Gynecologists. ACOG committee opinion no. 550: maternal-fetal surgery for myelomeningocele. *Obstet Gynecol.* 2013;121(1):218–9.
- 5 Boat A, Mahmoud M, Michelfelder EC, Lin E, Ngamprasertwong P, Schnell B, et al. Supplementing desflurane with intravenous anesthesia reduces fetal cardiac dysfunction during open fetal surgery. *Paediatr Anaesth.* 2010;20(8):748–56.
- 6 Ferschl M, Ball R, Lee H, Rollins MD. Anesthesia for in utero repair of myelomeningocele. *Anesthesiology.* 2013;118(5):1211–23.
- 7 Sinskey JL, Rollins MD, Whitlock E, Moon-Grady AJ, Vu L, Feiner JR, et al. Incidence and management of umbilical artery flow abnormalities during open fetal surgery. *Fetal Diagn Ther.* 2018;43(4):274–83.
- 8 Park WK, Kim MH, Ahn DS, Chae JE, Jee YS, Chung N, et al. Myocardial depressant effects of desflurane: mechanical and electrophysiologic actions in vitro. *Anesthesiology.* 2007;106(5):956–66.
- 9 Rychik J, Cohen D, Tran KM, Szwast A, Natarajan SS, Johnson MP, et al. The role of echocardiography in the intraoperative management of the fetus undergoing myelomeningocele repair. *Fetal Diagn Ther.* 2015;37(3):172–8.
- 10 Karsdorp VH, van Vugt JM, van Geijn HP, Kostense PJ, Arduini D, Montenegro N, et al. Clinical significance of absent or reversed end diastolic velocity waveforms in umbilical artery. *Lancet.* 1994;344(8938):1664–8.
- 11 Ngamprasertwong P, Michelfelder EC, Arabi S, Choi YS, Statile C, Ding L, et al. Anesthetic techniques for fetal surgery: effects of maternal anesthesia on intraoperative fetal outcomes in a sheep model. *Anesthesiology.* 2013;118(4):796–808.
- 12 Thind AS, Turner RJ. In vitro effects of propofol on gravid human myometrium. *Anaesth Intensive Care.* 2008;36(6):802–6.
- 13 Shin YK, Kim YD, Collea JV. The effect of propofol on isolated human pregnant uterine muscle. *Anesthesiology.* 1998;89(1):105–9.
- 14 Fanning RA, McMorro JP, Campion DP, Carey MF, O'Connor JJ. Opioid mediated activity and expression of mu and delta opioid receptors in isolated human term non-labouring myometrium. *Eur J Pharmacol.* 2013;698(1–3):170–7.
- 15 Eisenach JC, Kheterpal S, Houle TT. Reporting of observational research in ANESTHESIOLOGY: the importance of the analysis plan. *Anesthesiology.* 2016;124(5):998–1000.
- 16 Kinsella SM, Carvalho B, Dyer RA, Fernando R, McDonnell N, Mercier FJ, et al. International consensus statement on the management of hypotension with vasopressors during caesarean section under spinal anaesthesia. *Anaesthesia.* 2018;73(1):71–92.
- 17 Nickalls RW, Mapleson WW. Age-related iso-MAC charts for isoflurane, sevoflurane and desflurane in man. *Br J Anaesth.* 2003;91(2):170–4.
- 18 Hoagland MA, Chatterjee D. Anesthesia for fetal surgery. *Paediatr Anaesth.* 2017;27(8):873–57.
- 19 FDA. FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. 2016.
- 20 Bjur KA, Payne ET, Nemergut ME, Hu D, Flick RP. Anesthetic-related neurotoxicity and neuroimaging in children: a call for conversation. *J Child Neurol.* 2017;32(6):594–602.
- 21 Davidson AJ. Anesthesia and neurotoxicity to the developing brain: the clinical relevance. *Paediatr Anaesth.* 2011;21(7):716–21.
- 22 Ebert TJ. Cardiovascular and autonomic effects of sevoflurane. *Acta Anaesthesiol Belg.* 1996;47(1):15–21.
- 23 Van de Velde M, Van Schoubroeck D, Lewi LE, Marcus MA, Jani JC, Missant C, et al. Remifentanyl for fetal immobilization and maternal sedation during fetoscopic surgery: a randomized, double-blind comparison with diazepam. *Anesth Analg.* 2005;101(1):251–8.
- 24 Kan RE, Hughes SC, Rosen MA, Kessin C, Preston PG, Lobo EP. Intravenous remifentanyl: placental transfer, maternal and neonatal effects. *Anesthesiology.* 1998;88(6):1467–74.
- 25 Smith JA, Donepudi RV, Argoti PS, Giezen-tanner AL, Jain R, Boring N, et al. Exploring the pharmacokinetic profile of remifentanyl in mid-trimester gestations undergoing fetal intervention procedures. *Front Pharmacol.* 2017;8:11.
- 26 Santonocito C, Noto A, Crimi C, Sanfilippo F. Remifentanyl-induced postoperative hyperalgesia: current perspectives on mechanisms and therapeutic strategies. *Local Reg Anesth.* 2018;11:15–23.
- 27 DeSouza G, Lewis MC, TerRiet MF. Severe bradycardia after remifentanyl. *Anesthesiology.* 1997;87(4):1019–20.
- 28 Hinova A, Fernando R. Systemic remifentanyl for labor analgesia. *Anesth Analg.* 2009;109(6):1925–9.
- 29 Freeman LM, Bloemenkamp KW, Franssen MT, Papatsonis DN, Hajenius PJ, Hollmann MW, et al. Patient controlled analgesia with remifentanyl versus epidural analgesia in labour: randomised multicentre equivalence trial. *BMJ.* 2015;350:h846.
- 30 Liu ZQ, Chen XB, Li HB, Qiu MT, Duan T. A comparison of remifentanyl parturient-controlled intravenous analgesia with epidural analgesia: a meta-analysis of randomized controlled trials. *Anesth Analg.* 2014;118(3):598–603.
- 31 McClain DA, Hug CC Jr. Intravenous fentanyl kinetics. *Clin Pharmacol Ther.* 1980;28(1):106–14.